The American Partnership for Eosinophilic Disorders (APFED) is closely monitoring developments regarding the novel coronavirus (COVID-19) outbreak and the potential impact on the higher-risk patients in the eosinophil-associated disease community. This is a rapidly changing situation and we encourage you to follow updates on the Centers for Disease Control and Prevention (CDC)’s website and your state health department website.
COVID-19 was first detected in China in December 2019. It has since spread around the world, including to the United States, resulting in the World Health Organization (WHO) declaring a public health emergency of international concern and the United States Health and Human Services Secretary declaring a public health emergency.
Potential Impact on People with Eosinophil-Associated Diseases
There is not enough information as of yet, however, it appears that people with chronic health conditions, including those who have pulmonary or cardiac eosinophilic disorders, and those who take systemic corticosteroids and/or other immunosuppressive medications (e.g., methotrexate, cyclosporin, rituximab infusions) may be at higher risk of developing complications or more severe infection with COVID-19. Individuals should contact their healthcare provider if they have symptoms consistent with COVID-19.
CDC Information about COVID-19
Medical Reviewers: Gerald J. Gleich, MD, University of Utah Health; Michael E. Wechsler, MD, National Jewish Health; Praveen Akuthota, MD, UC San Diego Health.
Other Resources and Updates
- NEW APFED Resource: Managing Stress and Anxiety Amid COVID-19
- NEW CEGIR Announcement: A special COVID-19 related announcement from leadership of the Consortium for Eosinophilic Gastrointestinal Disease Researchers (CEGIR), addressing questions from patients with gastrointestinal subsets of eosinophil-associated diseases.
- NEW JACI Article: A look at eosinophil responses during COVID-19 infection and coronavirus vaccination has been released by the Journal of Allergy and Clinical Immunology (JACI). This is an expedited pre-proof version.
- TheFightIsInUs: A campaign focusing on recruiting COVID-19 survivors to donate plasma at licensed blood and plasma donor centers.
- Research survey for rare disease patients and their families about impacts of COVID-19: Rare disease patients or their caregivers are invited to complete a 20-minute online survey from home about the ways the novel coronavirus pandemic is impacting people with rare diseases and their families. Impacts can be related to physical health, emotional health, availability of supplies, access to care, or other problems. Your responses may help researchers understand the impacts of COVID-19 on the rare disease community.
The Rare Diseases Clinical Research Network (RDCRN) is conducting this study. The network is funded by the National Institutes of Health. It includes 23 research teams working to advance diagnosis and treatment of groups of rare diseases.
APFED partners with RDCRN through its work with the Consortium of Eosinophilic Gastrointestinal Disease Research.
To complete the survey or learn more, visit the study page here. Questions? Email the study team at firstname.lastname@example.org.
- The National Organization for Rare Disorders (NORD®) COVID-19 Critical Relief Program offers financial relief to members of the rare disease community affected by the COVID-19 pandemic
- FDA resources to help address questions patients may have about FDA-regulated medical products (drugs, biologics, devices) and COVID-19
- CDC resources for managing anxiety and stress
- Asthma and Allergy Foundation of America
- International FPIES Association
- Food Allergy & Anaphylaxis Connection Team
- Mastocytosis Society
- Message from Nutricia North America (makers of Neocate formula)
- Press Release from Takeda Pharmaceuticals on Patient Assistance During COVID-19 and Expanded Patient Assistance Statement